Ireland
--:--IST
Latest
Clinical Trials in France / NCT06017947
Recruiting Not applicable

Evaluation of a Musical Intervention on the Anxiety of Patients With a Diagnosis of Acute Coronary Syndrome in a Pre-Hospital Emergency Situation: MuSCA Randomized Controlled Trial

NCT06017947 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2023-09-12
Last updated
2026-09-16

Condition(s) studied

Acute Coronary Syndrome

Investigational drug(s) / intervention(s)

Music care

Music care: 20 min music listening during transportation to hospital

Study summary

Acute coronary syndrome (ACS) encompasses a continuum of clinical situations secondary to acute myocardial ischemia. In France, it is a major health problem and represented 60,000 to 65,000 hospitalizations in 2010. In 2015, a diagnosis of ACS was made in 15 to 25% of patients consulting for chest pain in emergency medicine.

The incidence of ACS is estimated between 80,000 and 100,000 new cases per year. At the University Hospital Center (CHU) of Réunion, acute chest pain is the leading cause of discharges from the Mobile Emergency and Resuscitation Service (SMUR). In 2019, it represented 23% of exits, 8.5% of which concerned SCAs.

The SCA can be anxiety-provoking due to its unexpected and brutal nature. Pain related to myocardial ischemia generates anxiety. This increases when patients associate these pains with death. This anxiety is exacerbated by waiting times for care, especially for patients living in rural areas. In addition, conditions relating to medical care such as noise and the pre-hospital medical environment are perceived as influencing anxiety by patients.

The prevalence of anxiety is high, ranging from 30 to 48.5%, in patients with chest pain and/or ACS. A 2020 meta-analysis revealed that anxious patients at the start of their ACS treatment had an increased risk of death, non-fatal myocardial infarction, rehospitalization, recurrence of ACS and the need for coronary revascularization repeated. Overall, ACS patients with anxiety have a 21% increased risk of mortality and 47% increased risk of adverse cardiovascular events compared to those without anxiety.

Pre-hospital anxiolytic treatment is therefore essential and consists above all in reassuring the patient with ACS. Medicated anxiolytics are often combined with analgesics and recommended in front of a picture of agitation due to anxiety. However, negative effects may interfere, making clinical monitoring of these patients unsuitable. At the same time, several studies note that anxiety is underdiagnosed and undertreated in the care of these patients.

In reducing the anxiety of patients with ACS, unconventional care techniques such as aromatherapy or touch massage have demonstrated their effectiveness. Music therapy is recognized in reducing the anxiety of patients in intensive care or Cardiology.

To the knowledge, in France, the effect of a musical intervention on patients with pre-hospital ACS has not yet been studied. It is in this context that the MuSCA study takes place.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged 18 and over * With an established or suspected Acute Coronary Syndrome diagnosis * With a stable clinical condition at the initial assessment: * Whose anxiety assessment is \> or = 30/100 mm on the Visual Analogue Scale * Having provided express, free and informed consent * With an estimated transport time of at least \> 30 minutes Exclusion Criteria: * Under guardianship, curatorship or judicial safeguard procedure * With hearing and visual impairments * Participating in another clinical trial or having already been included in this study. * Supported by helicopter

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Centre Hospitalier Universitaire Saint-Pierre Île de La Réunion Recruiting

More Centre Hospitalier Universitaire de la Réunion trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06017947 on ClinicalTrials.gov ↗ ← All trials in France